
*Elevated Lp(a) levels defined as ≥50 mg/dL or ≥125 nmol/L.1,8
Elevated Lp(a) is a unique and genetically determined condition that can increase risk for ASCVD5-7
Watch the video to see how Lp(a) testing can uncover a potential CV risk in patients with premature ASCVD (age <55 years in men, <65 years in women)—and their family members.2-4,8,9
Despite its clinical significance, Lp(a) levels are often not measured as part of a standard CV risk assessment8,10-12
*Atherogenicity was defined as the difference in coronary heart disease (CHD) risk per unit difference in Lp(a) or LDL particle number (molar concentration). This study was based principally on the UK Biobank population (>502,000 UK residents of mainly European ancestry). A replication cohort, the CARDIoGRAMplusC4D (Coronary ARtery DIsease Genome wide Replication and Meta-analysis [CARDIoGRAM] plus the Coronary Artery Disease Genetics) data set, was used to test the generalizability of the findings.13
Lp(a) levels are ~90% genetically determined, typically established by 5 years of age, relatively consistent over time, and generally not affected by diet or lifestyle1,2,5
In one study, the higher a person's Lp(a) level, the higher their risk for a lifetime CV event1
The CV risk from elevated Lp(a) is independent of other risk factors5,7-9,14-16
An elevated Lp(a) test result is actionable today and can help you better manage your patients' overall CV risk8,9
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; Lp(a), Lipoprotein(a).